Biotechnology Value Fund group (TCRX) reports 9.99% TScan ownership with large warrants

Rhea-AI Filing Summary

Biotechnology Value Fund and affiliates report significant ownership in TScan Therapeutics, Inc. (TCRX). As of June 30, 2026, BVF, BVF2, Trading Fund OS and related entities and a managed account beneficially owned an aggregate of 6,417,831 shares of Voting Common Stock, representing approximately 9.99% of the outstanding shares. This includes Pre-Funded Warrants exercisable for 1,219,288 shares at an exercise price of $0.0001 per share, which do not expire and are subject to a 9.99% beneficial ownership blocker that currently limits exercisability to 853,541 underlying shares. Individually, BVF holds 3,649,002 shares (about 5.7%) and BVF2 holds 2,662,237 shares (about 4.2%), with various BVF general partners and management entities deemed to share voting and dispositive power over these positions.

Key Figures

Aggregate beneficial ownership: 6,417,831 shares Aggregate ownership percentage: 9.99% BVF holdings: 3,649,002 shares +5 more

8 metrics

Aggregate beneficial ownership 6,417,831 shares Shares beneficially owned in aggregate by BVF, BVF2, Trading Fund OS and Partners Managed Account as of June 30, 2026

Aggregate ownership percentage 9.99% Approximate percentage of TScan Voting Common Stock beneficially owned by Partners, BVF Inc. and Mark N. Lampert

BVF holdings 3,649,002 shares Shares beneficially owned by Biotechnology Value Fund, L.P., including 547,031 warrant shares, about 5.7% of the class

BVF II holdings 2,662,237 shares Shares beneficially owned by Biotechnology Value Fund II, L.P., including 306,510 warrant shares, about 4.2% of the class

Pre-Funded Warrants aggregate 1,219,288 shares Total shares underlying Pre-Funded Warrants held by the Reporting Persons and a managed account

Exercisable under blocker 853,541 shares Portion of underlying Pre-Funded Warrant shares currently exercisable due to 9.99% ownership blocker

Exercise price of warrants $0.0001 per share Exercise price of the Pre-Funded Warrants, which do not expire

Shares outstanding baseline 61,074,229 shares Voting Common Stock outstanding as of May 1, 2026 used in ownership percentage calculations

Key Terms

Pre-Funded Warrants, Pre-Funded Warrants Blocker, beneficially owned, managed account, +1 more

5 terms

Pre-Funded Warrants financial

"held Pre-Funded Warrants (the "Pre-Funded Warrants") exercisable for an aggregate of 1,219,288 Shares."

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

Pre-Funded Warrants Blocker financial

"would cause the aggregate number of Shares beneficially owned ... to exceed 9.99% ... (the "Pre-Funded Warrants Blocker")."

beneficially owned financial

"As of the close of business on June 30, 2026, (i) BVF beneficially owned 3,649,002 Shares"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

managed account financial

"the Reporting Persons and a certain Partners managed account (the "Partners Managed Account") held Pre-Funded Warrants"

voting and dispositive power financial

"share voting and dispositive power over the Shares beneficially owned by BVF"

FAQ

What percentage of TScan Therapeutics (TCRX) does Biotechnology Value Fund report owning?

Biotechnology Value Fund and affiliated entities report beneficial ownership of 6,417,831 shares of TScan Therapeutics, representing approximately 9.99% of the outstanding Voting Common Stock as of June 30, 2026, including shares underlying certain Pre-Funded Warrants.

How many TScan Therapeutics (TCRX) shares do BVF and BVF II each beneficially own?

As of June 30, 2026, Biotechnology Value Fund, L.P. beneficially owns 3,649,002 shares (about 5.7%), and Biotechnology Value Fund II, L.P. beneficially owns 2,662,237 shares (about 4.2%) of TScan Therapeutics’ Voting Common Stock.

What are the key terms of the Pre-Funded Warrants held in TScan Therapeutics (TCRX)?

The Reporting Persons hold Pre-Funded Warrants exercisable for 1,219,288 shares of TScan Therapeutics at an exercise price of $0.0001 per share. The warrants do not expire and are subject to a 9.99% beneficial ownership blocker limiting exercisability.

How does the 9.99% blocker affect BVF’s TScan Therapeutics (TCRX) warrant exercises?

A 9.99% beneficial ownership blocker prevents exercises that would push ownership above 9.99% of outstanding shares. As of June 30, 2026, it limits exercise to 853,541 of the 1,219,288 underlying warrant shares held by the Reporting Persons and a managed account.

What share count did BVF use to calculate its TScan Therapeutics (TCRX) ownership percentages?

Ownership percentages are based on a denominator comprising 61,074,229 shares outstanding as of May 1, 2026, plus 2,314,783 shares issued on June 26, 2026 upon warrant exercise, and 853,541 shares issuable upon exercise of certain Pre-Funded Warrants.

Which BVF-related entity holds the largest deemed stake in TScan Therapeutics (TCRX)?

BVF GP Holdings LLC may be deemed to beneficially own 6,311,239 shares, or approximately 9.8% of TScan Therapeutics’ outstanding shares, through its interests in Biotechnology Value Fund and Biotechnology Value Fund II as of June 30, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 04:26 PM Accepted by SEC EDGAR 08/14/2026 - 04:19 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

TScan Therapeutics, Inc.

(Name of Issuer)

Voting Common Stock, $0.0001 par value per share

(Title of Class of Securities)

89854M101

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 89854M101

1

Names of Reporting Persons

BIOTECHNOLOGY VALUE FUND L P

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,649,002.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,649,002.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,649,002.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.7 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 89854M101

1

Names of Reporting Persons

BVF I GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,649,002.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,649,002.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,649,002.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.7 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 89854M101

1

Names of Reporting Persons

BIOTECHNOLOGY VALUE FUND II LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,662,237.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,662,237.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,662,237.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.2 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 89854M101

1

Names of Reporting Persons

BVF II GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,662,237.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,662,237.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,662,237.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.2 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 89854M101

1

Names of Reporting Persons

Biotechnology Value Trading Fund OS LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 83,135.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 83,135.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

83,135.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.1 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 89854M101

1

Names of Reporting Persons

BVF Partners OS Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 83,135.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 83,135.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

83,135.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.1 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP Number(s): 89854M101

1

Names of Reporting Persons

BVF GP HOLDINGS LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,311,239.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,311,239.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,311,239.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.8 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 89854M101

1

Names of Reporting Persons

BVF PARTNERS L P/IL

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,417,831.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,417,831.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,417,831.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

CUSIP Number(s): 89854M101

1

Names of Reporting Persons

BVF INC/IL

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,417,831.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,417,831.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,417,831.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP Number(s): 89854M101

1

Names of Reporting Persons

LAMPERT MARK N

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,417,831.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,417,831.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,417,831.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: TScan Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 830 WINTER STREET, WALTHAM, MA 02451
Item 2.
(a)	Name of person filing: Biotechnology Value Fund, L.P. ("BVF") BVF I GP LLC ("BVF GP") Biotechnology Value Fund II, L.P. ("BVF2") BVF II GP LLC ("BVF2 GP") Biotechnology Value Trading Fund OS LP ("Trading Fund OS") BVF Partners OS Ltd. ("Partners OS") BVF GP Holdings LLC ("BVF GPH") BVF Partners L.P. ("Partners") BVF Inc. Mark N. Lampert ("Mr. Lampert") Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."
(b)	Address or principal business office or, if none, residence: Biotechnology Value Fund, L.P. 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF I GP LLC 44 Montgomery St., 40th Floor San Francisco, California 94104 Biotechnology Value Fund II, L.P. 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF II GP LLC 44 Montgomery St., 40th Floor San Francisco, California 94104 Biotechnology Value Trading Fund OS LP PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands BVF Partners OS Ltd. PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands BVF GP Holdings LLC 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF Partners L.P. 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF Inc. 44 Montgomery St., 40th Floor San Francisco, California 94104 Mark N. Lampert 44 Montgomery St., 40th Floor San Francisco, California 94104
(c)	Citizenship: Biotechnology Value Fund, L.P. Delaware BVF I GP LLC Delaware Biotechnology Value Fund II, L.P. Delaware BVF II GP LLC Delaware Biotechnology Value Trading Fund OS LP Cayman Islands BVF Partners OS Ltd. Cayman Islands BVF GP Holdings LLC Delaware BVF Partners L.P. Delaware BVF Inc. Delaware Mark N. Lampert United States
(d)	Title of class of securities: Voting Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 89854M101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of the close of business on June 30, 2026, the Reporting Persons and a certain Partners managed account (the "Partners Managed Account") held Pre-Funded Warrants (the "Pre-Funded Warrants") exercisable for an aggregate of 1,219,288 Shares. The Pre-Funded Warrants are exercisable at any time at an exercise price of $0.0001 per Share and do not expire. A holder of Pre-Funded Warrants will not have the right to exercise any portion of its Pre-Funded Warrants which, upon giving effect to such exercise, would cause the aggregate number of Shares beneficially owned by the holder (together with its affiliates and other attribution parties (as defined in the Pre-Funded Warrant)) to exceed 9.99% of the Shares outstanding immediately after such exercise (the "Pre-Funded Warrants Blocker"). As of the close of business on June 30, 2026, the Pre-Funded Warrants Blocker limits the exercise of the Pre-Funded Warrants held by the Reporting Persons and the Partners Managed Account to 853,541 out of the 1,219,288 Shares underlying the Pre-Funded Warrants held by them. As of the close of business on June 30, 2026, (i) BVF beneficially owned 3,649,002 Shares, including 547,031 Shares underlying the Pre-Funded Warrants held by it, (ii) BVF2 beneficially owned 2,662,237 Shares, including 306,510 Shares underlying certain Pre-Funded Warrants held by it and excluding 94,743 Shares underlying certain Pre-Funded Warrants held by it, and (iii) Trading Fund OS beneficially owned 83,135 Shares, excluding 220,094 Shares underlying the Pre-Funded Warrants held by it. BVF GP, as the general partner of BVF, may be deemed to beneficially own the 3,649,002 Shares beneficially owned by BVF. BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 2,662,237 Shares beneficially owned by BVF2. Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 83,135 Shares beneficially owned by Trading Fund OS. BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 6,311,239 Shares beneficially owned in the aggregate by BVF and BVF2. Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 6,417,831 Shares beneficially owned in the aggregate by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, including 23,457 Shares held in the Partners Managed Account, which excludes 50,910 Shares underlying the Pre-Funded Warrants held in the Partners Managed Account. BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 6,417,831 Shares beneficially owned by Partners. Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 6,417,831 Shares beneficially owned by BVF Inc. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.
(b)	Percent of class: The following percentages are based upon a denominator that is the sum of: (i) 61,074,229 Shares outstanding as of May 1, 2026, which is the total number of Shares outstanding as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 6, 2026, (ii) 2,314,783 Shares issued to the Reporting Persons and Partners Managed Account on June 26, 2026 upon the exercise of certain Pre-Funded Warrants previously held by the Reporting Persons and Partners Managed Account, as applicable, and (iii) 853,541 Shares issuable upon the exercise of certain Pre-Funded Warrants held by the Reporting Persons, as applicable. As of the close of business on June 30, 2026, (i) BVF beneficially owned approximately 5.7% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 4.2% of the outstanding Shares, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own approximately 5.7% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own approximately 4.2% of the outstanding Shares, (vi) Partners OS may be deemed to beneficially own less than 1% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 9.8% of the outstanding Shares, and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 9.99% of the outstanding Shares (less than 1% of the outstanding Shares are held in the Partners Managed Account).
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Cover Pages Items 5-9.
	(ii) Shared power to vote or to direct the vote: See Cover Pages Items 5-9.
	(iii) Sole power to dispose or to direct the disposition of: See Cover Pages Items 5-9.
	(iv) Shared power to dispose or to direct the disposition of: See Cover Pages Items 5-9.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. BVF GP, BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF. BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF2. Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by Trading Fund OS and held in the Partners Managed Account.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. See Exhibit 99.1 to the Schedule 13G filed with the Securities and Exchange Commission on June 5, 2023.
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BIOTECHNOLOGY VALUE FUND L P

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	08/14/2026

BVF I GP LLC

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	08/14/2026

BIOTECHNOLOGY VALUE FUND II LP

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	08/14/2026

BVF II GP LLC

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	08/14/2026

Biotechnology Value Trading Fund OS LP

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	08/14/2026

BVF Partners OS Ltd.

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	08/14/2026

BVF GP HOLDINGS LLC

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	08/14/2026

BVF PARTNERS L P/IL

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	08/14/2026

BVF INC/IL

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	08/14/2026

LAMPERT MARK N

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert
Date:	08/14/2026